scholarly journals Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017

2020 ◽  
Vol 26 (2) ◽  
pp. 209-215 ◽  
Author(s):  
Seung Ha Park ◽  
Lindsay D. Plank ◽  
Ki Tae Suk ◽  
Yong Eun Park ◽  
Jin Lee ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Chronic Liver Disease ◽  
Adult Population ◽  
Chronic Liver ◽  
Excessive Alcohol Consumption ◽  
Alcoholic Fatty Liver ◽  
Future Burden ◽  
Definition Of ◽  
Hepatic Steatosis Index

Data on the trends in the prevalence of chronic liver disease (CLD) in Korea are scarce. This study aimed to evaluate whether the CLD prevalence changed between 1998–2001 and 2016–2017. Data were extracted from the Korea National Health and Nutrition Examination Survey (1998–2001 to 2016–2017; n=25,893). Non-alcoholic fatty liver disease (NAFLD) was defined as a hepatic steatosis index >36 in the absence of any other evidence of CLD. The definition of alcoholrelated liver disease (ALD) was excessive alcohol consumption (≥210 g/week for men and ≥140 g/week for women) and an ALD/NAFLD index >0. The prevalence of NAFLD increased from 18.6% (95% confidence interval [CI], 17.8–19.5%) in 1998–2001 to 21.5% (95% CI, 20.6–22.6%) in 2016–2017. During the same time period, increases were observed in the prevalence of obesity (27.0 vs. 35.1%), central obesity (29.4 vs. 36.0%), diabetes (7.5 vs. 10.6%), and excessive drinking (7.3 vs. 10.5%). ALD prevalence also increased from 3.8% (95% CI, 3.4–4.2%) to 7.0% (95% CI, 6.4–7.6%). In contrast, chronic hepatitis B decreased from 5.1% (95% CI, 4.6–5.5%) to 3.4% (95% CI, 3.0–3.8%). The prevalence of chronic hepatitis C was approximately 0.3% in 2016–2017. The prevalence of NAFLD and ALD increase among Korean adults. Our results suggest potential targets for interventions to reduce the future burden of CLD.

scholarly journals Combination of FIB-4 with ultrasound surface nodularity or elastography as predictors of histologic advanced liver fibrosis in chronic liver disease

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Maryam Moini ◽  
Fernanda Onofrio ◽  
Bettina E. Hansen ◽  
Oyedele Adeyi ◽  
Korosh Khalili ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Transient Elastography ◽  
Area Under The Curve ◽  
High Specificity ◽  
Serum Markers ◽  
Chronic Liver ◽  
Alcoholic Fatty Liver ◽  
Advanced Liver Fibrosis ◽  
Independent Association

AbstractReliable and available non-invasive methods for hepatic fibrosis assessment are important in chronic liver disease (CLD). Our aim was to compare stepwise algorithms combining standard ultrasound with serum markers and transient elastography (TE) for detecting advanced fibrosis (F3-4) and cirrhosis. Retrospective single center study between 2012 and 2018 of CLD patients with biopsy, TE, blood tests, and liver ultrasound parameters of surface nodularity (SN), lobar redistribution, and hepatic vein nodularity. Our cohort included 157 patients (51.6% males), mean age 47.6 years, predominantly non-alcoholic fatty liver disease and viral hepatitis (61%), with F3-4 prevalence of 60.5%. Area under the curve for F3-4 was 0.89 for TE ≥ 9.6 kPa and 0.80 for FIB-4 > 3.25. In multivariate modeling, TE ≥ 9.6 kPa (OR 21.78) and SN (OR 3.81) had independent association with F3-4; SN (OR 5.89) and TE ≥ 10.2 kPa (OR 15.73) were independently associated with cirrhosis. Two stepwise approaches included FIB-4 followed by SN or TE; sensitivity and specificity of stepwise SN were 0.65 and 1.00, and 0.89 and 0.33 for TE ≥ 9.6 kPa, respectively. Ultrasound SN and TE were independently predictive of F3-4 and cirrhosis in our cohort. FIB-4 followed by SN had high specificity for F3-4.

scholarly journals Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease

Hepatology ◽  
1997 ◽  
Vol 25 (5) ◽  
pp. 1271-1275 ◽  
Author(s):  
M W Fried ◽  
Y E Khudyakov ◽  
G A Smallwood ◽  
M Cong ◽  
B Nichols ◽  
...  
Keyword(s):  
Liver Transplantation ◽  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver ◽  
Hepatitis G Virus ◽  
Hepatitis G

P.469 Diabetes is associated with chronic liver disease and liver cancer in the adult population of Puerto Rico

2006 ◽  
Vol 36 ◽  
pp. S206
Author(s):  
A.P. Ortiz ◽  
C. Pérez ◽  
C.J. Romero ◽  
O. Disdier ◽  
E. Santana ◽  
...  
Keyword(s):  
Puerto Rico ◽  
Liver Disease ◽  
Liver Cancer ◽  
Chronic Liver Disease ◽  
Adult Population ◽  
Chronic Liver

Integrin up-regulation in chronic liver disease: relationship with inflammation and fibrosis in chronic hepatitis C

2001 ◽  
Vol 195 (4) ◽  
pp. 473-481 ◽  
Author(s):  
Mimoun Nejjari ◽  
Anne Couvelard ◽  
Jean-Fran�ois Mosnier ◽  
Alain Moreau ◽  
G�rard Feldmann ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Chronic Liver Disease ◽  
Chronic Hepatitis C ◽  
Chronic Liver

scholarly journals Characteristics of opioid prescribing to outpatients with chronic liver diseases: A call for action

PLoS ONE ◽  
2021 ◽  
Vol 16 (12) ◽  
pp. e0261377
Author(s):  
Olufunso M. Agbalajobi ◽  
Theresa Gmelin ◽  
Andrew M. Moon ◽  
Wheytnie Alexandre ◽  
Grace Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
High Risk ◽  
Chronic Liver Disease ◽  
Medical Center ◽  
Chronic Liver ◽  
Prescribing Patterns ◽  
Prescription Opioid ◽  
Alcoholic Fatty Liver ◽  
Opioid Prescribing ◽  
One Year

Background Chronic liver disease (CLD) is among the strongest risk factors for adverse prescription opioid-related events. Yet, the current prevalence and factors associated with high-risk opioid prescribing in patients with chronic liver disease (CLD) remain unclear, making it challenging to address opioid safety in this population. Therefore, we aimed to characterize opioid prescribing patterns among patients with CLD. Methods This retrospective cohort study included patients with CLD identified at a single medical center and followed for one year from 10/1/2015-9/30/2016. Multivariable, multinomial regression was used identify the patient characteristics, including demographics, medical conditions, and liver-related factors, that were associated with opioid prescriptions and high-risk prescriptions (≥90mg morphine equivalents per day [MME/day] or co-prescribed with benzodiazepines). Results Nearly half (47%) of 12,425 patients with CLD were prescribed opioids over a one-year period, with 17% of these receiving high-risk prescriptions. The baseline factors significantly associated with high-risk opioid prescriptions included female gender (adjusted incident rate ratio, AIRR = 1.32, 95% CI = 1.14–1.53), Medicaid insurance (AIRR = 1.68, 95% CI = 1.36–2.06), cirrhosis (AIRR = 1.22, 95% CI = 1.04–1.43) and baseline chronic pain (AIRR = 3.40, 95% CI = 2.94–4.01), depression (AIRR = 1.93, 95% CI = 1.60–2.32), anxiety (AIRR = 1.84, 95% CI = 1.53–2.22), substance use disorder (AIRR = 2.16, 95% CI = 1.67–2.79), and Charlson comorbidity score (AIRR = 1.27, 95% CI = 1.22–1.32). Non-alcoholic fatty liver disease was associated with decreased high-risk opioid prescriptions (AIRR = 0.56, 95% CI = 0.47–0.66). Conclusion Opioid medications continue to be prescribed to nearly half of patients with CLD, despite efforts to curtail opioid prescribing due to known adverse events in this population.

scholarly journals Peran Terlipressin pada Penyakit Hati Kronik

2021 ◽  
Vol 3 (1) ◽  
pp. 24
Author(s):  
Decky Andrea ◽  
Luciana Rotty
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Chronic Liver Disease ◽  
Variceal Bleeding ◽  
Hepatorenal Syndrome ◽  
Chronic Liver ◽  
Refractory Ascites ◽  
Esophageal Variceal ◽  
Alcoholic Fatty Liver ◽  
Esophageal Variceal Bleeding

Abstract: Chronic liver disease is a progressive impairment of liver function. It is caused by non-alcoholic fatty liver, viral infection of the liver, excessive alcohol consumption, metabolic diseases such as galactosemia, autoimmune disease, and the influence of chemicals. Complications that are often found are esophageal variceal bleeding, hepatorenal syndrome, and refractory ascites. Terlipressin, which is a vasopressin analogue, is currently widely used in developed countries because it has been shown to improve survival of patients with esophageal varices, hepatorenal syndrome, and refractory ascites. Terlipressin is the current standard therapy for esophageal variceal bleeding in countries where it is available.Keywords: chronic liver disease; terlipressin  Abstrak: Penyakit hati kronis (PHK) adalah gangguan fungsi hati yang terjadi secara progresif. Peyakit hati kronis di sebabkan oleh non-alcoholic fatty liver, infeksi virus pada hati, konsumsi alkohol berlebihan, peyakit metabolik seperti galaktosemia, penyakit autoimun, dan pengaruh bahan kimia. Komplikasi yang sering ditemukan pada PHK ialah perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Terlipressin yang merupakan analog vasopressin saat ini banyak di pakai di negara maju karena terbukti dapat meningkatkan kelangsungan hidup pasien perdarahan varises esofagus, sindrom hepatorenal, dan asites refrakter. Dewasa ini terlipressin telah menjadi terapi standar perdarahan varises esofagus di negara-negara di mana obat ini tersedia.Kata kunci: penyakit hati kronik; terlipressin

Detecting chronic liver disease: are liver function tests the solution?

2020 ◽  
Vol 81 (2) ◽  
pp. 1-8
Author(s):  
Prarthana Thiagarajan ◽  
Jane Chalmers ◽  
Indra N Guha ◽  
Martin W James
Keyword(s):  
Liver Disease ◽  
Liver Function ◽  
Chronic Liver Disease ◽  
Liver Function Tests ◽  
Chronic Liver ◽  
Alcoholic Fatty Liver ◽  
Non Invasive ◽  
Function Tests ◽  
Life Years ◽  
The Uk

By 2020, chronic liver disease will have eclipsed ischaemic heart disease as the leading cause of working life years lost in the UK. As mortality from chronic liver disease continues to rise, the landscape of aetiology has shifted from infectious to non-communicable causes. In parallel with the growing prevalence of obesity and type 2 diabetes, non-alcoholic fatty liver disease is estimated to affect 25% of the UK adult population. Simultaneously, escalating alcohol consumption has fuelled public health and economic concerns regarding its widespread impact on working-age adults. Given that chronic liver disease remains clinically silent until its advanced stages, there is an urgent unmet need to identify affected individuals earlier in the disease process, enabling targeted intervention strategies which may improve prognosis. Robust epidemiological data have shown that liver fibrosis is the strongest predictor of clinically meaningful outcomes, including decompensation, liver cancer and overall mortality. Detecting fibrosis among at-risk individuals, in a manner that is reproducible, non-invasive, safe and cost effective, has become a major challenge of our time. This article addresses the pitfalls of the standard panel of liver function tests, discusses other non-invasive biomarkers and reviews imaging technologies which may revolutionise community-based diagnosis and stratification of chronic liver disease.

Sign in / Sign up

Export Citation Format

Share Document